Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
VUG vs XBI: how they differ
VUG and XBI hold 1% of their weight in the same names, and XBI returned more over the year.
Vanguard Growth Index Fund and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, VUG and XBI hold 1% of their money in the same securities at the same weight.
| Holding | VUG | XBI |
|---|---|---|
| Vertex Pharmaceuticals Inc | 0.36% | 1.06% |
| Alnylam Pharmaceuticals Inc | 0.13% | 0.96% |
| Insmed Inc | 0.05% | 1.08% |
| Only in VUG | Only in XBI |
|---|---|
| NVIDIA Corp 12.63% | Apogee Therapeutics Inc 1.49% |
| Apple Inc 11.67% | Moderna Inc 1.41% |
| Microsoft Corp 7.62% | Twist Bioscience Corp 1.41% |
| Alphabet Inc 5.76% | Oruka Therapeutics Inc 1.38% |
| Alphabet Inc 4.54% | Kymera Therapeutics Inc 1.36% |
| Amazon.com Inc 4.47% | Viking Therapeutics Inc 1.31% |
| Broadcom Inc 4.29% | Praxis Precision Medicines Inc 1.29% |
| Meta Platforms Inc 3.41% | Erasca Inc 1.27% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026.
| VUG Vanguard Growth Index Fund | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Vanguard | State Street |
| What it is | US growth | SPDR S&P Biotech |
| Total return, 1 year | +12.9% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −4.6 pts | +46.5 pts |
| Expense ratio | 0.03% | 0.35% |
| Already in the S&P 500 | 97.4% | 8.5% |
| Holdings | 147 | 150 |
VUG in plain words
VUG is an index equity fund tracking the US growth. Over the year to Sep 11, 2026 it returned +12.9% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.03% a year. By its holdings filed for Jun 30, 2026, 97% of the fund by weight is stocks the S&P 500 also holds, across 147 positions, with the top ten at 60.5%.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, VUG or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, VUG returned +12.9% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, VUG or XBI?
- VUG charges 0.03% a year and XBI charges 0.35%, so VUG is cheaper. Fees come from each fund's prospectus.
- How much do VUG and XBI overlap with the S&P 500?
- By their latest filed holdings, 97% of VUG and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 1% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, VUG against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/VUG-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources